<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2026-3-117-124</article-id><article-id custom-type="edn" pub-id-type="custom">RUMZGR</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-556</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ ФАРМАКОКИНЕТИКИ И ФАРМАКОДИНАМИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL STUDIES OF PHARMACOKINETICS AND PHARMACODYNAMICS</subject></subj-group></article-categories><title-group><article-title>Влияние блокатора АТФ-зависимых калиевых каналов глибенкламида на нефропротективный эффект полидатина при цисплатин-индуцированном остром повреждении почек</article-title><trans-title-group xml:lang="en"><trans-title>Influence of the ATP-sensitive potassium channel blocker glibenclamide on the nephroprotective effect of polydatin in cisplatin-induced acute kidney injury</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2212-0508</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нетребенко</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Netrebenko</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нетребенко Александр Сергеевич — к. м. н., ассистент кафедры фармакологии и клинической фармакологии</p><p>Белгород </p></bio><bio xml:lang="en"><p>Alexander S. Netrebenko — PhD, Cand. Sci. (Med.), Assistant Professor, Department of Pharmacology and Clinical Pharmacology</p><p>Belgorod </p></bio><email xlink:type="simple">AlexNetrebenko@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2761-6249</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Покровский</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pokrovsky</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Покровский Михаил Владимирович — д. м. н., профессор, профессор кафедры фармакологии и клинической фармакологии, руководитель Научно-исследовательского института фармакологии живых систем</p><p>Белгород </p></bio><bio xml:lang="en"><p>Mikhail V. Pokrovsky — Dr. Sci. (Med.), Professor, Professor of the Department of Pharmacology and Clinical Pharmacology, Head of the Research Institute of Pharmacology of Living Systems</p><p>Belgorod </p></bio><email xlink:type="simple">mpokrovsky@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6121-2128</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бессмертный</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bessmertniy</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бессмертный Дмитрий Васильевич — к. м. н., врач-онколог</p><p>Белгород</p></bio><bio xml:lang="en"><p>Dmitry V. Bessmertniy — PhD, Cand. Sci. (Med.), oncologist</p><p>Belgorod </p></bio><email xlink:type="simple">Bessmertniy@oncology31.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Белгородский государственный национальный исследовательский университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Belgorod State National Research University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ОГБУЗ «Белгородский областной онкологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Belgorod regional oncology clinic</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2026</year></pub-date><volume>0</volume><issue>3</issue><fpage>117</fpage><lpage>124</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нетребенко А.С., Покровский М.В., Бессмертный Д.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Нетребенко А.С., Покровский М.В., Бессмертный Д.В.</copyright-holder><copyright-holder xml:lang="en">Netrebenko A.S., Pokrovsky M.V., Bessmertniy D.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/556">https://www.pharmacokinetica.ru/jour/article/view/556</self-uri><abstract><p>Актуальность. Острое повреждение почек — грозный патологический процесс, часто развивающийся на фоне химиотерапии цисплатином. Ранее была продемонстрирована способность фитоалексина полидатина к снижению негативного влияния цисплатина на функцию почек. Однако механизмы, благодаря которым реализуется нефропротективный потенциал полидатина, окончательно не установлены.Цель. Изучить влияние блокатора АТФ-зависимых калиевых каналов глибенкламида на реализацию нефропротективного эффекта полидатина при моделировании цисплатин-индуцированного острого повреждения почек.Материалы и методы. Исследование проведено на 50 белых лабораторных крысах-самцах линии Wistar массой 250–300 г, которые были разделены на 5 групп (n = 10). Моделирование острого почечного повреждения осуществлялось путём внутрибрюшинного введения цисплатина в дозе 5 мг/кг в 1-й и 8-й дни эксперимента. С целью нефропротекции ежедневно внутрижелудочно вводили полидатин в дозе 12 мг/кг. Для блокировки АТФ-зависимых калиевых каналов использовался глибенкламид внутрижелудочно в дозе 5 мг/кг за 30 минут до введения полидатина. Спустя 14 суток после первого введения цисплатина оценивали лабораторные и инструментальные показатели функции почек.Результаты. Адекватное функционирование АТФ-зависимых калиевых каналов играет важную роль в реализации нефропротективных свойств полидатина при моделировании цисплатин-индуцированного острого повреждения почек. Введение глибенкламида с целью блока K+АТФ-каналов совместно с полидатином сопровождалось достоверным падением защитного потенциала последнего: возрастали показатели азотемии, ухудшались скорость клубочковой фильтрации и фракционная экскреция натрия, снижался уровень микроциркуляции в почках. На фоне падения показателя микроциркуляции также возрастал уровень протеинурии.Выводы. АТФ-зависимые калиевые каналы имеют большое влияние на реализацию нефропротективного потенциала полидатина при моделировании цисплатин-индуцированного острого повреждения почек.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. Acute kidney injury is a serious pathological process that often develops during treatment with cisplatin. The ability of the phytoalexin polydatin to reduce the negative impact of cisplatin on kidney function has previously been demonstrated. However, the mechanisms by which polydatin exerts its nephroprotective potential have not been fully elucidated.Objective. To investigate the effect of the ATP-sensitive potassium channel blocker glibenclamide on the implementation of the nephroprotective effect of polydatin in modeling cisplatin-induced acute kidney injury.Materials and methods. The study was conducted on 50 white laboratory male Wistar rats weighing 250-300g, which were divided into 5 groups (n = 10). Modeling of acute kidney injury was carried out by intraperitoneal administration of cisplatin at a dose of 5 mg/kg on the 1st and 8th days of the experiment. For the purpose of nephroprotection, polydatin was administered intragastrically daily at a dose of 12 mg/kg. To block ATP-sensitive potassium channels, glibenclamide was used intragastrically at a dose of 5 mg/kg 30 minutes before the administration of polydatin. 14 days after the first administration of cisplatin, laboratory and instrumental indicators of renal function were assessed.Results. Adequate functioning of ATP-sensitive potassium channels plays a key role in the nephroprotective properties of polydatin in a model of cisplatin-induced acute kidney injury. Administration of glibenclamide to block ATP-sensitive potassium channels, combined with polydatin, was associated with a significant decrease in the protective potential of the latter: increased azotemia, deterioration of the glomerular filtration rate and fractional sodium excretion, and decreased renal microcirculation. Against the background of a decrease in the microcirculation index, the level of proteinuria also increased.Conclusions. ATP-sensitive potassium channels have a significant influence on the implementation of the nephroprotective potential of polydatin in the modeling of cisplatin-induced acute kidney injury.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>полидатин</kwd><kwd>АТФ-зависимые калиевые каналы</kwd><kwd>цисплатин</kwd><kwd>острое повреждение почек</kwd><kwd>микроциркуляция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>polydatin</kwd><kwd>ATP-sensitive potassium channels</kwd><kwd>cisplatin</kwd><kwd>acute kidney injury</kwd><kwd>microcirculation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang M, Bai M, Lei J, et al. Mitochondrial dysfunction and the AKIto-CKD transition. Am J Physiol Renal Physiol. 2020 Dec 1;319(6):F1105-F1116. doi: 10.1152/ajprenal.00285.2020.</mixed-citation><mixed-citation xml:lang="en">Jiang M, Bai M, Lei J, et al. Mitochondrial dysfunction and the AKIto-CKD transition. Am J Physiol Renal Physiol. 2020 Dec 1;319(6):F1105-F1116. doi: 10.1152/ajprenal.00285.2020.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бурнашева Е.В., Шатохин Ю.В., Снежко И.В., Мацуга А.А. Поражение почек при противоопухолевой терапии. Нефрология. 2018;22(5):17-24. doi: 10.24884/1561-6274-2018-22-5-17-24</mixed-citation><mixed-citation xml:lang="en">Burnasheva EV, Shatokhin YV, Snezhko IV, Matsuga AA. Kidney injury in cancer therapy. Nephrology (Saint-Petersburg). 2018;22(5):17-24. (In Russ.). doi: 10.24884/1561-6274-2018-22-5-17-24</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta S, Glezerman IG, Hirsch JS, et al. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ. 2024 Mar 27;384:e077169. doi: 10.1136/bmj-2023-077169. Erratum in: BMJ. 2024 Jun 20;385:q1207. doi: 10.1136/bmj.q1207.</mixed-citation><mixed-citation xml:lang="en">Gupta S, Glezerman IG, Hirsch JS, et al. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ. 2024 Mar 27;384:e077169. doi: 10.1136/bmj-2023-077169. Erratum in: BMJ. 2024 Jun 20;385:q1207. doi: 10.1136/bmj.q1207.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Чеботарева Н.В., Цыгин А.Н., Буланов Н.М. Синдром Фанкони у взрослых и детей. Клиническая фармакология и терапия. 2022;31(1): 69-74. doi: 10.32756/0869-5490-2022-1-69-74.</mixed-citation><mixed-citation xml:lang="en">Chebotareva N, Tsygin A, Bulanov N. Fan coni syndrome in adults and children. Klinicheskaya farmakologiya i terapiya. 2022;31(1):69-74. (In Russ.). doi: 10.32756/0869-5490-2022-1-69-74.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Waikar SS, Mogg R, Baker AF, et al. Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury. Clin Pharmacol Ther. 2025 May;117(5):1272-1283. doi: 10.1002/cpt.3531.</mixed-citation><mixed-citation xml:lang="en">Waikar SS, Mogg R, Baker AF, et al. Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury. Clin Pharmacol Ther. 2025 May;117(5):1272-1283. doi: 10.1002/cpt.3531.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pinard L, Adam JP, Chagnon M, et al. Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin. J Oncol Pharm Pract. 2025 Jul;31(5):754-760. doi: 10.1177/10781552241262248.</mixed-citation><mixed-citation xml:lang="en">Pinard L, Adam JP, Chagnon M, et al. Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin. J Oncol Pharm Pract. 2025 Jul;31(5):754-760. doi: 10.1177/10781552241262248.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Сергеева Н.С., Кармакова Т.А., Савчина В.В. и др. KIM-1 и другие маркеры острого повреждения почек при цисплатин-индуцированной нефротоксичности. Вестник РАМН. 2024;79(4):327-337. doi: 10.15690/vramn17959.</mixed-citation><mixed-citation xml:lang="en">Sergeeva NS, Karmakova TA, Savchina VV, et al. KIM-1 and Other Markers of Acute Kidney Injury in Cisplatin-Induced Nephrotoxicity. Annals of the Russian Academy of Medical Sciences. 2024;79(4):327-337. (In Russ.). doi: 10.15690/vramn17959.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Motwani SS, McMahon GM, Humphreys BD, et al. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161.</mixed-citation><mixed-citation xml:lang="en">Motwani SS, McMahon GM, Humphreys BD, et al. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fang CY, Lou DY, Zhou LQ, et al. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin. 2021 Dec;42(12):1951-1969. doi: 10.1038/s41401-021-00620-9. Epub 2021 Mar 9. Erratum in: Acta Pharmacol Sin. 2023 Feb;44(2):488. doi: 10.1038/s41401-022-01012-3.</mixed-citation><mixed-citation xml:lang="en">Fang CY, Lou DY, Zhou LQ, et al. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin. 2021 Dec;42(12):1951-1969. doi: 10.1038/s41401-021-00620-9. Epub 2021 Mar 9. Erratum in: Acta Pharmacol Sin. 2023 Feb;44(2):488. doi: 10.1038/s41401-022-01012-3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Netrebenko AS, Pokrovskaya TG, Netrebenko EG, et al. Modeling of cisplatin-induced acute kidney injury and its correction using polydatin. Research Results in Pharmacology. 2026;12(2): 35-45. doi: 10.18413/rrpharmacology.12.1072.</mixed-citation><mixed-citation xml:lang="en">Netrebenko AS, Pokrovskaya TG, Netrebenko EG, et al. Modeling of cisplatin-induced acute kidney injury and its correction using polydatin. Research Results in Pharmacology. 2026;12(2): 35-45. doi: 10.18413/rrpharmacology.12.1072.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Karami A, Fakhri S, Kooshki L, Khan H. Polydatin: Pharmacological Mechanisms, Therapeutic Targets, Biological Activities, and Health Benefits. Molecules. 2022 Oct 1;27(19):6474. doi: 10.3390/molecules27196474.</mixed-citation><mixed-citation xml:lang="en">Karami A, Fakhri S, Kooshki L, Khan H. Polydatin: Pharmacological Mechanisms, Therapeutic Targets, Biological Activities, and Health Benefits. Molecules. 2022 Oct 1;27(19):6474. doi: 10.3390/molecules27196474.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Li CSZ, Yu B, Gao Q, et al. The critical role of ion channels in kidney disease: perspective from AKI and CKD. Ren Fail. 2025 Dec;47(1):2488139. doi: 10.1080/0886022X.2025.2488139.</mixed-citation><mixed-citation xml:lang="en">Li CSZ, Yu B, Gao Q, et al. The critical role of ion channels in kidney disease: perspective from AKI and CKD. Ren Fail. 2025 Dec;47(1):2488139. doi: 10.1080/0886022X.2025.2488139.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rahgozar M, Willgoss DA, Gobé GC, Endre ZH. ATP-dependent K+ channels in renal ischemia reperfusion injury. Ren Fail. 2003 Nov;25(6):885-96. doi: 10.1081/jdi-120026024.</mixed-citation><mixed-citation xml:lang="en">Rahgozar M, Willgoss DA, Gobé GC, Endre ZH. ATP-dependent K+ channels in renal ischemia reperfusion injury. Ren Fail. 2003 Nov;25(6):885-96. doi: 10.1081/jdi-120026024.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ho FJM, Siow CJR, Aljaibeji H, et al. UNI-494 treatment improves measures of renal dysfunction and cardiac pathology in male rats receiving L-NAME and angiotensin II. Physiol Rep. 2025 Nov;13(21):e70634. doi: 10.14814/phy2.70634.</mixed-citation><mixed-citation xml:lang="en">Ho FJM, Siow CJR, Aljaibeji H, et al. UNI-494 treatment improves measures of renal dysfunction and cardiac pathology in male rats receiving L-NAME and angiotensin II. Physiol Rep. 2025 Nov;13(21):e70634. doi: 10.14814/phy2.70634.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dowlatshahi K, Ajami M, Pazoki-Toroudi H, Hajimiresmaiel SJ. ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/ reperfusion injury. Med J Islam Repub Iran. 2015 Mar 14;29:191.</mixed-citation><mixed-citation xml:lang="en">Dowlatshahi K, Ajami M, Pazoki-Toroudi H, Hajimiresmaiel SJ. ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/ reperfusion injury. Med J Islam Repub Iran. 2015 Mar 14;29:191.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Netrebenko AS. Correction of renal ischemia/reperfusion injury with the combination of Infliximab and the erythropoietin-derived peptide mimetic pHBSP. Research Results in Pharmacology. 2023;9(2):85-97. doi: 10.18413/rrpharmacology.9.10032.</mixed-citation><mixed-citation xml:lang="en">Netrebenko AS. Correction of renal ischemia/reperfusion injury with the combination of Infliximab and the erythropoietin-derived peptide mimetic pHBSP. Research Results in Pharmacology. 2023;9(2):85-97. doi: 10.18413/rrpharmacology.9.10032.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Topcu A, Saral S, Mercantepe T, et al. The effects of apelin-13 against cisplatin-induced nephrotoxicity in rats. Drug Chem Toxicol. 2023 Jan;46(1):77-87. doi: 10.1080/01480545.2021.2011309.</mixed-citation><mixed-citation xml:lang="en">Topcu A, Saral S, Mercantepe T, et al. The effects of apelin-13 against cisplatin-induced nephrotoxicity in rats. Drug Chem Toxicol. 2023 Jan;46(1):77-87. doi: 10.1080/01480545.2021.2011309.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gong Q, Wang M, Jiang Y, et al. The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point. Pharmacol Res Perspect. 2021 Dec;9(6):e00895. doi: 10.1002/prp2.895.</mixed-citation><mixed-citation xml:lang="en">Gong Q, Wang M, Jiang Y, et al. The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point. Pharmacol Res Perspect. 2021 Dec;9(6):e00895. doi: 10.1002/prp2.895.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gong Q, Yin J, Wang M, et al. Comprehensive study of dexamethasone on albumin biogenesis during normal and pathological renal conditions. Pharm Biol. 2020 Dec;58(1):1252-1262. doi: 10.1080/13880209.2020.1855214.</mixed-citation><mixed-citation xml:lang="en">Gong Q, Yin J, Wang M, et al. Comprehensive study of dexamethasone on albumin biogenesis during normal and pathological renal conditions. Pharm Biol. 2020 Dec;58(1):1252-1262. doi: 10.1080/13880209.2020.1855214.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kostina DA, Pokrovskaya TG, Poltev VY. Renoprotective effect of carbamylated darbepoetin and udenafil in ischemia-reperfusion of rat kidney due to the effect of preconditioning and inhibition of nuclear factor kappa B. Research Results in Pharmacology. 2021;7(1):1-19. doi: 10.3897/rrpharmacology.7.63059.</mixed-citation><mixed-citation xml:lang="en">Kostina DA, Pokrovskaya TG, Poltev VY. Renoprotective effect of carbamylated darbepoetin and udenafil in ischemia-reperfusion of rat kidney due to the effect of preconditioning and inhibition of nuclear factor kappa B. Research Results in Pharmacology. 2021;7(1):1-19. doi: 10.3897/rrpharmacology.7.63059.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Shabelnikova A. Correction of ischemic damage to the retina on application of pharmacological preconditioning of recombinant erythropoietin. Research Results in Pharmacology. 2016;2(2):67-90. doi: 10.18413/2313-8971-2016-2-2-67-90.</mixed-citation><mixed-citation xml:lang="en">Shabelnikova A. Correction of ischemic damage to the retina on application of pharmacological preconditioning of recombinant erythropoietin. Research Results in Pharmacology. 2016;2(2):67-90. doi: 10.18413/2313-8971-2016-2-2-67-90.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Даниленко Л.М. Роль митохондриальных АТФ-зависимых калиевых каналов в кардиопротекторном эффекте никорандила на модели коронарооклюзионного инфаркта миокарда. Сетевой журнал «Научный результат». Серия «Медицина и фармация». 2015;1(4(6)):40-44. doi: 10.18413/2313-8955-2015-1-4-40-44.</mixed-citation><mixed-citation xml:lang="en">Danilenko LM. The role of mitochondrial atp-dependent potassium channels in the cardioprotective effect nicorandilа on the model koronarolitikov myocardial infarctio. Research Result. Medicine and pharmacy series. 2015;1(4(6)):40-44. (In Russ.). doi: 10.18413/2313-8955-2015-1-4-40-44.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yu B, Jin L, Yao X, et al. TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy. Theranostics. 2023 Jul 31;13(13):4356-4375. doi: 10.7150/thno.84655.</mixed-citation><mixed-citation xml:lang="en">Yu B, Jin L, Yao X, et al. TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy. Theranostics. 2023 Jul 31;13(13):4356-4375. doi: 10.7150/thno.84655.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang LP, Yang CY, Wang YP, et al. ATP-sensitive potassium channel and mitochondrial permeability transition pore involve in cadioprotection of polydatin. Chinese Journal of Pharmacology and Toxicology. 2009;23(2):81-88. doi: 10.3867/j.issn.1000-3002.2009.02.001.</mixed-citation><mixed-citation xml:lang="en">Zhang LP, Yang CY, Wang YP, et al. ATP-sensitive potassium channel and mitochondrial permeability transition pore involve in cadioprotection of polydatin. Chinese Journal of Pharmacology and Toxicology. 2009;23(2):81-88. doi: 10.3867/j.issn.1000-3002.2009.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang LP, Wei Y, Song SL, et al. Effect of polydatin on action potential in ventricular papillary muscle of rat and the underlying ionic mechanism. Sheng Li Xue Bao. 2011 Feb 25;63(1):48-54. PMID: 21340434.</mixed-citation><mixed-citation xml:lang="en">Zhang LP, Wei Y, Song SL, et al. Effect of polydatin on action potential in ventricular papillary muscle of rat and the underlying ionic mechanism. Sheng Li Xue Bao. 2011 Feb 25;63(1):48-54. PMID: 21340434.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kaya ST, Bozdogan O, Ozarslan TO, et al. The protection of resveratrol and its combination with glibenclamide, but not berberine on the diabetic hearts against reperfusion-induced arrhythmias: the role of myocardial KATP channel. Arch Physiol Biochem. 2019 May;125(2):114-121. doi: 10.1080/13813455.2018.1440409.</mixed-citation><mixed-citation xml:lang="en">Kaya ST, Bozdogan O, Ozarslan TO, et al. The protection of resveratrol and its combination with glibenclamide, but not berberine on the diabetic hearts against reperfusion-induced arrhythmias: the role of myocardial KATP channel. Arch Physiol Biochem. 2019 May;125(2):114-121. doi: 10.1080/13813455.2018.1440409.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol. 2007;69:51-67. doi: 10.1146/annurev.physiol.69.031905.163645.</mixed-citation><mixed-citation xml:lang="en">Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Annu Rev Physiol. 2007;69:51-67. doi: 10.1146/annurev.physiol.69.031905.163645.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, O'Rourke B. Opening of mitochondrial K(ATP) channels triggers cardioprotection. Are reactive oxygen species involved? Circ Res. 2001 Apr 27;88(8):750-2. doi: 10.1161/hh0801.090537.</mixed-citation><mixed-citation xml:lang="en">Liu Y, O'Rourke B. Opening of mitochondrial K(ATP) channels triggers cardioprotection. Are reactive oxygen species involved? Circ Res. 2001 Apr 27;88(8):750-2. doi: 10.1161/hh0801.090537.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Левченкова О.С., Новиков В.Е., Пожилова Е.В. Митохондриальная пора как мишень фармакологического воздействия. Вестник Смоленской государственной медицинской академии. 2014;13(4):24-33.</mixed-citation><mixed-citation xml:lang="en">Levchenkova OS, Novikov VE, Pozhilova EV. Mitochondrial pore as a pharmacological target. Vestnik of Smolensk state medical academy. 2014;13(4):24-33. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira BM, de Almeida LF, Deluque AL, et al. Calcitriol Reduces the Inflammation, Endothelial Damage and Oxidative Stress in AKI Caused by Cisplatin. Int J Mol Sci. 2022 Dec 14;23(24):15877. doi: 10.3390/ijms232415877.</mixed-citation><mixed-citation xml:lang="en">Oliveira BM, de Almeida LF, Deluque AL, et al. Calcitriol Reduces the Inflammation, Endothelial Damage and Oxidative Stress in AKI Caused by Cisplatin. Int J Mol Sci. 2022 Dec 14;23(24):15877. doi: 10.3390/ijms232415877.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gaballah RM, Sallam MY, Elblehi SS, et al. Empagliflozin mitigated cisplatin induced renal endothelial dysfunction in rats via repressing oxidative, inflammatory, apoptotic and fibrotic signals. Biomed Pharmacother. 2026 Jun;199:119436. doi: 10.1016/j.biopha.2026.119436.</mixed-citation><mixed-citation xml:lang="en">Gaballah RM, Sallam MY, Elblehi SS, et al. Empagliflozin mitigated cisplatin induced renal endothelial dysfunction in rats via repressing oxidative, inflammatory, apoptotic and fibrotic signals. Biomed Pharmacother. 2026 Jun;199:119436. doi: 10.1016/j.biopha.2026.119436.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024 Jul 13;404(10448):145-155. doi: 10.1016/S0140-6736(24)00537-3.</mixed-citation><mixed-citation xml:lang="en">Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024 Jul 13;404(10448):145-155. doi: 10.1016/S0140-6736(24)00537-3.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Hang X, Ma J, Wei Y, et al. Renal microcirculation and mechanisms in diabetic kidney disease. Front Endocrinol (Lausanne). 2025 Jun 5;16:1580608. doi: 10.3389/fendo.2025.1580608.</mixed-citation><mixed-citation xml:lang="en">Hang X, Ma J, Wei Y, et al. Renal microcirculation and mechanisms in diabetic kidney disease. Front Endocrinol (Lausanne). 2025 Jun 5;16:1580608. doi: 10.3389/fendo.2025.1580608.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
